emergency use authorization (EUA) to two COVID-19 vaccines, one by Pfizer-BioNtech and one by Moderna.As a result, in the coming months, millions of the most vulnerable people in the U.S.
will receive a vaccine that protects them against the disease.This is good news, but it does pose an ethical dilemma for researchers conducting ongoing clinical trials of these and other COVID-19 vaccines.